GEO series

Prolonged KRAS-MAPK Inhibition Induces Interferon-mediated Epithelial-to-Mesenchymal Transition and Reveals Therapeutic Opportunities [scRNAseq-Ulixertinib]

GSE303104 Mus musculus (mouse) Single-cell RNA-seq 2 samples Submitted 2026/03/25 Platform GPL21493

At a glance

Single-cell RNA-seq · mouse · 2 samples

What it is: Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart.
Organism: Mus musculus (mouse)
Samples: 2 samples
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper: Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic VulnerabilitiesCancer research · 2026

Summary (written by the submitters)

Direct targeting of KRAS to inhibit the MAPK cascade is poised to transform the therapeutic landscape of pancreatic ductal adenocarcinoma (PDAC). However, analyses of PDAC samples from patients treated with KRASG12C inhibitors have revealed secondary mutations restoring MAPK signaling and promoting epithelial-to-mesenchymal transition (EMT) as key mechanisms of acquired resistance.

Read the full summary ↓

Here, we show that human PDAC specimens and patient-derived cell lines treated with the ERK inhibitor ulixertinib display upregulation of EMT-associated and inflammatory gene programs, particularly those linked to the interferon response. Using the GeneRep-nSCORE computational framework to reconstruct and rank regulatory networks enriched in ERKi and KRASi-resistant PDAC cells, we identified TRIM22, an interferon-inducible E3 ubiquitin ligase, as a critical mediator of EMT and treatment resistance. Mechanistically, TRIM22 promotes proteasomal degradation of IκBα, leading to activation of NF-κB signaling, a known driver of EMT. Notably, we identify TACSTD2, encoding Trophoblast Cell Surface Antigen 2 (TROP2), as an NF-κB target gene upregulated following EMT. Functionally, combining ulixertinib or the KRAS inhibitor MRTX1133 with the TROP2-directed antibody-drug conjugate sacituzumab govitecan significantly suppressed the growth of PDAC patient-derived xenografts. Together, our work identifies TRIM22 as a molecular link between interferon signaling and EMT and reveals TROP2 as a druggable vulnerability to sustain the therapeutic efficacy of KRAS-MAPK pathway inhibitors.

Published in

Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities

Bulle A, Chen Y, Li H et al. · Cancer research 2026 · PMID 42008116 · doi:10.1158/0008-5472.CAN-25-4114

This dataset

Open GSE303104 in finder → Find more mouse RNA-seq datasets →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE303104_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.

Also filed as BioProject PRJNA1294179 and SRA study SRP602540. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 42008116) ↗

Samples in this study

The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.

+ 2 more — browse all 2 samples with per-sample file links →

Datasets on a similar topic

GSE303105 Prolonged KRAS-MAPK Inhibition Induces Interferon-mediated Epithelial-to-Mesenchymal Transition and Reveals Therapeutic Opportunities [scRNAseq-RMC-6236] 2 samples shares epithelial-to-mesenchymal, interferon-mediated, opportunities, therapeutic, inhibition, transition, prolonged
GSE278530 JAK inhibition results in aggressive cutaneous squamous cell carcinoma through MAPK pathway activation and shapes the tumor immune microenvironment to create novel therapeutic opportunities [RNA-seq] 7 samples shares opportunities, therapeutic, inhibition
GSE319705 CD47 promotes MAPK and epithelial-to-mesenchymal transition molecular programs to drive pro-metastatic phenotypes in non-small cell lung cancer 9 samples shares epithelial-to-mesenchymal, transition
GSE248436 c-Abl-induced Wnt/β-catenin activation and Ksp-tdTomato+ PDGFRα+ tubular epithelial cells promote renal fibrosis in mice through epithelial-to-mesenchymal transition 6 samples shares epithelial-to-mesenchymal, transition
GSE97110 Role of TERRA lncRNA during epithelial-to-mesenchymal transition 4 samples shares epithelial-to-mesenchymal, transition
GSE297456 Threonine Phosphorylation of STAT1 Safeguards Gut Epithelial Integrity and Restricts Interferon-mediated Cytotoxicity [RNA-seq] 16 samples shares interferon-mediated
GSE252968 Age-dependent differences in the tumor microenvironment of preclinical models of triple-negative breast cancer: challenges and opportunities for efficacy studies. 8 samples shares opportunities
GSE276317 Sleep fragmentation aggravates myocardial infarction through promoting type I interferon-mediated SiglecFhi neutrophil expansion 6 samples shares interferon-mediated

Search all mouse RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.